Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors
Authors:
Open Access
- 16 September 2024
- journal article
- review article
- Published by KEAI Publishing in Global Medical Genetics
- Vol. 11 (4) , 330-343
Abstract
The fibroblast growth factor receptor (FGFR) is a crucial receptor tyrosine kinase involved in essential biological processes, including growth, development, and tissue repair. However, FGFR gene mutations, including amplification, fusion, and mutation, can disrupt epigenetics, transcriptional regulation, and tumor microenvironment interactions, leading to cancer development. Targeting these kinase mutations with small molecule drugs or antibodies has shown clinical benefits. For example, erdafitinib is approved for treating locally advanced or metastatic urothelial cancer patients with FGFR2/FGFR3 mutations, and pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement. Effective screening of FGFR variant patients is crucial for the clinical application of FGFR inhibitors. Various detection methods, such as polymerase chain reaction, next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry, are available, and their selection should be based on diagnostic and treatment decision-making needs. Our developed expert consensus aims to standardize the diagnosis and treatment process for FGFR gene mutations and facilitate the practical application of FGFR inhibitors in clinical practice. Y.L., W.F., Z.L., and Y.S. participated in the design of the expert consensus. C.X., B.L., J.O., Q.W., W.W., K.W., and D.W. conceived of the expert consensus and participated in its design and other authors coordination and helped to draft the expert consensus. All authors read and approved the final manuscript. # These authors contributed equally. Article published online: 16 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 66 references indexed in Scilit:
- Evaluation of FGFR Alteration Status in Urothelial Tumors2023
- A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced CancerTargeted Oncology, 2017
- Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New HopeCancer Treatment Reviews, 2016
- Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumorsActa Neuropathologica, 2016
- Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathwayCancer Treatment Reviews, 2014
- Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumoursThe Journal of Pathology, 2013
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Cellular signaling by fibroblast growth factor receptorsCytokine & Growth Factor Reviews, 2005
- Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): Phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3American Journal of Medical Genetics, 1999
- Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.The EMBO Journal, 1996